{"id":"W4390048145","doi":"10.1002/cncr.35151","title":"NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Holden Comprehensive Cancer Center, University of Iowa; University of Oklahoma Health Sciences Center; Seagen; NRG Oncology; Eisai; Alvin J. Siteman Cancer Center; AstraZeneca; University of Oklahoma; Natera; GlaxoSmithKline","keywords":"Olaparib; Medicine; Internal medicine; Oncology; Hazard ratio; Clinical endpoint; PARP inhibitor; BRCA mutation; Randomized controlled trial; Ovarian cancer; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002376485,0.00173461,0.002489733,0.0004754997,0.0002876156,0.0008547755,0.001104363,0.001443702,0.008211678],"category_scores_gemma":[0.001780823,0.0008349681,0.001711883,0.0004700448,0.001128424,0.000885313,0.0003870134,0.002262159,0.001280627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008774971,"about_ca_system_score_gemma":0.00173234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00094494,"about_ca_topic_score_gemma":0.00369209,"domain_scores_codex":[0.9991171,0.000606015,0.00004338822,0.0001037284,0.00005598896,0.00007382914],"domain_scores_gemma":[0.9992284,0.0002061714,0.0001705013,0.00006140023,0.00004375921,0.0002898411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9702832,0.009580854,0.000916582,0.0004532592,0.0006152332,0.00005178412,0.00003881955,0.0002971193,0.00384472,0.00006733606,0.000726443,0.01312465],"study_design_scores_gemma":[0.9374847,0.06064513,0.0008829794,0.00001565162,0.0001717082,0.00003666711,0.000009575236,0.0001703743,0.0001964348,0.0000439417,0.0003353191,0.000007521009],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843019,0.003975208,0.000639982,0.0008697557,0.0005181252,0.005790093,0.001631677,0.0001749608,0.002098281],"genre_scores_gemma":[0.9820415,0.002942593,0.002220221,0.001820055,0.0004945453,0.00467863,0.002314652,0.00003162113,0.00345617],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008211678,"threshold_uncertainty_score":0.02747077,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07955989394311878,"score_gpt":0.3855548167263008,"score_spread":0.305994922783182,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}